

October 1, 2021

Effective immediately, Manitoba is adopting the September 28, 2021 National Advisory Committee on Immunization (NACI) guidance on co-administration of COVID-19 vaccines with other vaccines.

NACI recommends that COVID-19 vaccines may be given concomitantly with, or at any time before or after, other vaccines.*

***including live, non-live, adjuvanted, or unadjuvanted vaccines.**

NACI has concluded that a precautionary approach to co-administration of the COVID-19 vaccine is now no longer necessary (i.e., waiting 14 or 28 days between vaccines depending on which vaccine was administered first), and recommends that vaccines may be administered concomitantly with (i.e. same day), or any time before, non-COVID-19 vaccines (including live, non-live, adjuvanted, or unadjuvanted). The concomitant administration of COVID-19 with non-COVID-19 vaccines will facilitate influenza vaccine programs in the fall and winter months and other routine vaccine programs that were disrupted due to the COVID-19 pandemic.

Informed consent should include a discussion of the benefits and risks given the limited data available on administration of COVID-19 vaccines with other vaccines. Studies to assess the safety and immunogenicity of concurrent administration of COVID-19 vaccines with other vaccines are ongoing.

It is currently not known if the reactogenicity of COVID-19 vaccines is increased with concomitant administration of other vaccines. While no specific safety concerns have been identified for various other vaccines with concomitant administration regimens, there is potential for increased reactogenicity with concomitant administration of COVID-19 vaccines with other vaccines, particularly those known to be more reactogenic, such as newer adjuvanted vaccines.

If more than one type of vaccine is administered at a single visit, they should be administered at different injection sites using separate injection equipment. NACI will continue to monitor the evidence and update recommendations as needed.

Please share this information with all relevant colleagues in your facility/clinic.

Sincerely,

“Original Signed by”

Richard Baydack, PhD
Director
Communicable Disease Control

“Original Signed by”

Tim Hilderman, MD FRCPC
Medical Lead, Vaccines
Communicable Disease Control